Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study

Imagem de Miniatura
Arquivos
art_OLIVEIRA_Effects_of_Hepatitis_C_virus_on_cardiovascular_risk_2013.PDF (605.97 KB)
Citações na Scopus
73
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
KAPPEL, C. R.
SIQUEIRA, E. R.
MICHALCZUK, M. T.
MARINI, S. S.
Citação
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.164, n.2, p.221-226, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The role of hepatitis C virus (HCV) in the pathogenesis of atherosclerosis and cardiovascular events is unclear. The aim of this study was to evaluate the direct effect of HCV on cardiovascular risk and correlate it with pro and anti-inflammatory cytokines in patients with HCV. HCV monoinfected patients, genotype 1, naive, non-obese (BMI<30) and non-diabetics were included and compared to controls (blood donors). Patients with prior diagnosis of cardiovascular diseases, hypertension, chronic renal failure, cancer and chronic use of lipid-lowering drugs or immunosuppressants were excluded. Age, BMI, systolic blood pressure (SBP) and diastolic (DBP), fasting glucose and lipid levels were determined. Serum cytokines (IL-6, IL-10 and TNF-alpha) and Framingham score were also evaluated. 62 HCV patients, 34 (54.8%) were males and none of them was smoking. The Framingham scores (median and 25th and 75th percentiles) were 12% (6.5-14%), showing an intermediate cardiovascular risk in patients with HCV. There was significant direct correlation between Framingham and total cholesterol (p=0.043) and DBP (p=0.007). HDL-C (p=0.002) was inversely correlated with the Framingham score. HCV patients had higher levels of proinflammatory cytokines (IL-6 and TNF-alpha) compared to controls (p<0.0001) and the relation of proinflammatory/anti-inflammatory TNF-alpha/IL10 and IL-6/IL10 were higher in HCV patients (p<0.01). The Framingham score was directly correlated to IL-6 and TNF-alpha, but differences were not statistically significant. Patients with HCV monoinfected, nonobese, naive and non diabetic have an intermediate cardiovascular risk, as measured by the Framingham score and high levels of proinflammatory cytokines (IL-6 and TNF).
Palavras-chave
Hepatitis C virus, Cardiovascular risk, Framingham Score, Pro-inflammatory cytokines
URI
https://observatorio.fm.usp.br/handle/OPI/1939
Referências
  1. Abbas Z, 2003, J Pak Med Assoc, V53, P59
  2. ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259
  3. ANDERSON C, 1991, NATURE, V353, P289
  4. ANDERSON KM, 1991, CIRCULATION, V83, P356
  5. Armstrong GL, 2006, ANN INTERN MED, V144, P705
  6. Boddi Maria, 2007, Dig Liver Dis, V39 Suppl 1, pS55, DOI 10.1016/S1590-8658(07)80012-0
  7. Brown PMJ, 2001, CLIN BIOCHEM, V34, P167, DOI 10.1016/S0009-9120(01)00210-7
  8. Chen Y, 2007, AM J PHYSIOL-RENAL, V293, P680
  9. Clement S, 2009, VIRUSES-BASEL, V1, P126, DOI 10.3390/v1020126
  10. Corey KE, 2009, HEPATOLOGY, V50, P1030, DOI 10.1002/hep.23219
  11. Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1
  12. de Waal MR, 1991, J EXP MED, V174, P915, DOI 10.1084/JEM.174.4.915
  13. de Waal M.R., 1991, J EXP MED, V174, P1209
  14. Fartoux L, 2005, GUT, V54, P1003, DOI 10.1136/gut.2004.050302
  15. Fernandez-Real JM, 1999, DIABETOLOGIA, V42, P1367, DOI 10.1007/s001250051451
  16. FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
  17. Floris-Moore M, 2007, AIDS PATIENT CARE ST, V21, P479, DOI 10.1089/apc.2006.0150
  18. Freiberg MS, 2007, AIDS, V21, P193, DOI 10.1097/QAD.0b013e3280118a0d
  19. Fukui M, 2003, JAMA-J AM MED ASSOC, V289, P1245, DOI 10.1001/jama.289.10.1245-b
  20. Gruady SM, 2004, CIRCULATION, V109, P551
  21. Guiltinan AM, 2008, AM J EPIDEMIOL, V167, P743, DOI 10.1093/aje/kwm370
  22. Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220
  23. Ishizaka N, 2002, LANCET, V359, P133, DOI 10.1016/S0140-6736(02)07339-7
  24. Lecube A, 2006, DIABETES CARE, V29, P1096, DOI 10.2337/dc05-2509
  25. Llorente L, 1996, J HEPATOL, V24, P555, DOI 10.1016/S0168-8278(96)80140-1
  26. Maggi G, 1996, ITAL J GASTROENTEROL, V28, P436
  27. Marzouk D, 2007, GUT, V56, P1105, DOI 10.1136/gut.2006.091983
  28. Milner KL, 2010, GASTROENTEROLOGY, V138, P932, DOI 10.1053/j.gastro.2009.11.050
  29. Mostafa A, 2010, GUT, V59, P1135, DOI 10.1136/gut.2009.202317
  30. Negro F, 2009, J VIRAL HEPATITIS, V16, P681, DOI 10.1111/j.1365-2893.2009.01186.x
  31. Persico M, 2007, HEPATOLOGY, V46, P1009, DOI 10.1002/hep.21782
  32. Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA
  33. Syed GH, 2009, TRENDS ENDOCRIN MET, V21, P33
  34. Tsui JI, 2009, J CARD FAIL, V15, P451, DOI [10.1016/j.cardfail.2008.12.003, 10.1016/j.cardfail.2009.12.003]
  35. Tsuruma T, 1998, CELL IMMUNOL, V184, P121, DOI 10.1006/cimm.1998.1266
  36. Vassalle C, 2004, HEART, V90, P565, DOI 10.1136/hrt.2003.018937
  37. Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545
  38. Yue FY, 1997, INT J CANCER, V71, P630, DOI 10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E
  39. Zeller JC, 1999, J IMMUNOL, V163, P3684

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/51
Artigos e Materiais de Revistas Científicas - ODS/03